- To understand current pharmacotherapies that are used in the treatment of substance use disorders
- To recognize challenges associated with treatment of substance use disorders in special populations (including pregnancy and chronic pain)
- To understand legal, policy, and administrative issues of relevance to the clinical practice of addiction medicine
The University of Alabama School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Alabama School of Medicine designates this educational activity for a maximum of 7.75 “AMA PRA Category 1 Credit(s)™.” Physicians should only claim credit commensurate with the extent of their participation in the activity. The University of Alabama School of Medicine is an equal opportunity/affirmative action institution.
Certificate of Attendance
A Certificate of Attendance issued by the American College of Medical Toxicology is also available for all attendees on a request basis. Please request during registration and check-in March 26, 2015.
8:00-8:50am - Disordered Behavior: The Neurobiology and Underlying Basis of Craving, Relapse and Addiction
Eliot L. Gardner, PhD, Chief of Neuropsychopharmacology Section Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD
8:50-9:25am - Bench to Bedside: From the Science to the Practice of Addiction Medicine
Petros Levounis, MD, MA, Chair, Department of Psychiatry, Rutgers New Jersey Medical School; Chief of Service, Department of Psychiatry, University Hospital, Newark, NJ
9:25-9:45am - Break
9:45-10:25am - The New Kid on the Block: Incorporating Buprenorphine into a Medical Toxicology Practice
Timothy J. Wiegand, MD, FACMT, Director of Toxicology, University of Rochester Medicine, Rochester, NY; Medical Director, Huther Doyle Chemical Dependency Treatment Program, Rochester, NY
10:25-11:15am - Chronic Pain, Chronic Opioids Addiction: A Complex Nexus
11:15 -11:55am - CASE STUDIES
Clinical Cases: Drug & Alcohol Dependence & Pain
Faculty: JoAn Laes, MD; Petros Levounis, MD, MA, FASAM; Edwin A. Salsitz, MD, FASAM; Daniel L. Sudakin, MD, MPH, FACMT; Timothy J. Wiegand, MD, FACMT
11:55am-1:10pm - Lunch on your own
1:10-1:40pm - Naltrexone: Not Just for Opioids Anymore
Daniel L. Sudakin, MD, MPH, FACMT, Director of Addiction Medicine, Pathways Northwest (Philomath,OR), Affiliate faculty, Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR
1:40-2:20pm - Methadone Maintenance: Putting a Real Face on the Demon
Edwin A. Salsitz, MD, FASAM
2:20-2:55pm - Special Populations and Addictive Disorders Panel - Case Discussion
Panelists: Daniel L. Sudakin, MD, MPH, FACMT; Timothy J. Wiegand, MD, FACMT; Edwin A. Salsitz, MD, FASAM; JoAn Laes, MD
2:55-3:10pm - Break
3:10-3:40pm - Small Group Discussion: Legal and Policy Issues in Addiction Medicine
Faculty: Timothy J. Wiegand, MD, FACMT; Daniel L. Sudakin, MD, MPH, FACMT; Edwin A. Salsitz, MD, FASAM; Petros Levounis, MD, MA; JoAn Laes ,MD
3:40-4:20pm - Screening and Counseling: Beyond the Meds in Addiction Medicine
4:20-5:05pm - Addiction Medicine Training and Practice
Kevin B. Kunz, MD, MPH, Vice-President, American Board of Addiction Medicine, Medical Director, Hawaii Physicians Program, Clinical Instructor, Department of Psychiatry, School of Medicine, University of Hawaii, Honolulu, HI
5:05-5:35pm - The Integration of Medical Toxicology and Addiction Medicine: New Era in Patient Care
Eliot L. Gardner, PhD is Senior Investigator and Chief of Neuropsycholpharmacology Section Intramural Research Program at the National Institute on Drug Abuse, National Institutes of Health in Baltimore, MD. His research is directed toward the development of effective anti-addiction, anti-craving, and anti-relapse medications and includes: basic brain mechanisms underlying drug addiction, craving, and relapse; endocannabinoid brain mechanisms and addiction; dopamine D3 receptor antagonists; glutamatergic compounds, with emphasis on the metabotropic glutamate receptor; GABAergic agonists, with emphasis on the GABA-B receptor; slow-onset long-acting dopamine transport inhibitors; and drugs acting on the endocannabinoid brain system. Dr. Gardner completed post-doctoral training in neurology and pharmacology at Albert Einstein College of Medicine after completing his PhD in physiological psychology at McGill University. (Click here for selected publications).
Dr. Levounis is a Phi Beta Kappa graduate of Stanford University where he studied Chemistry and Biophysics as a combined BS/MS student, before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he researched the effects of social class on patient-physician relationships in Oxford, England, and received an MA degree in Sociology from Stanford. In 1994, he moved to New York City to train in Psychiatry at the New York State Psychiatric Institute of Columbia University. He graduated from Columbia receiving the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in Addiction Psychiatry at New York University under the mentorship of Dr. Marc Galanter. During that time, he received the American Psychiatric Association/Center for Mental Health Services Minority Fellowship, which supported his research on HIV risk factors in homeless men who suffer from severe mental illness and substance use disorders. In 2006, Dr. Levounis completed the Leadership Development for Physicians in Academic Health Centers Program at Harvard School of Public Health.
Dr. Levounis has authored over 50 articles, monographs, and book chapters; has lectured extensively on addiction topics throughout the United States and abroad; and has been interviewed by CBS, ABC, NBC, CNN, FOX, The Martha Stewart Radio Show, The New York Times, and The Washington Post, among others. He is a Betty Ford Scholar; a member and Laughlin Fellow of the American College of Psychiatrists; and a recipient of the 2008 Coalition Leadership Award, the Irma Bland Award for Excellence in Teaching Residents, the Nancy Roeske Award for Excellence in Medical Student Education, the U.S. State Department Speaker and Specialist Award, and the Association of Gay and Lesbian Psychiatrists’ 2012 Distinguished Service Award. Dr. Levounis serves on the boards of the American Society of Addiction Medicine (ASAM) and the American Board of Addiction Medicine (ABAM) and from 2005 to 2009 chaired the national Committee on Addiction Treatment of the American Psychiatric Association (APA). Dr. Levounis is an ASAM Fellow and a Distinguished Fellow of the APA.
Dr. Levounis has authored/edited nine books including the self-help paperback “Sober Siblings: How to Help Your Alcoholic Brother or Sister—and Not Lose Yourself” (Perseus 2008), the textbook of “Substance Dependence and Co-Occurring Psychiatric Disorders” (Civic Research Institute 2010), the handbook of “Motivation and Change” (American Psychiatric Publishing 2010), the handbook of “Office-Based Buprenorphine Treatment of Opioid Dependence” (APP 2011), the award-winning and translated “LGBT Casebook” (APP 2012), “The Addiction Casebook” (APP 2014) based on the DSM-5, and “The Behavioral Addictions” (APP 2015), an innovative book that includes re-enactment video clips played by Rutgers NJMS medical students. He is currently working on the American Psychiatric Publishing’s “Pocket Guide to Addiction Assessment and Treatment,” which is expected to be available in early 2016.
Dr. Levounis is married to actor Lukas Hassel and lives in New York City.
Edwin A. Salsitz, MD, FASAM is an attending physician at Mount Sinai Beth Israel, Division of Chemical Dependency. Dr. Salsitz is the principal investigator of the Methadone Medical Maintenance research project. He received his medical degree from SUNY Buffalo School of Medicine. Dr. Salsitz is board certified in Internal Medicine, Pulmonary Medicine and Addiction Medicine. He belongs to the American Society of Addiction Medicine and has had the opportunity to contribute to various publications and lectures frequently on addiction medicine topics. Dr. Salsitz is a member of the medical advisory panel for the New York State Office of Alcohol and Substance Abuse Services. He was named in the 2011 edition of Castle Connolly’s “Top Doctors: New York Metro Area.”
Dr. Salsitz received the prestigious American Society of Addiction Medicine 2014 Annual Award for his committment and unwavering dedication to education and professional development within ASAM.
Daniel L. Sudakin, MD, MPH, FACMT, FACOEM is the Director of Addiction Medicine at Pathways Northwest, in Philomath, Oregon. Pathways Northwest is an outpatient addiction medicine practice, focusing on the treatment of opioid and other substance use disorders. He is board certified in Preventive Medicine, and in the subspecialty of Medical Toxicology. He completed a preventive medicine residency and medical toxicology fellowship at Oregon Health and Science University. Prior to transitioning to the clinical practice of addiction medicine, Dr. Sudakin was an Associate Professor in the Department of Environmental and Molecular Toxicology at Oregon State University. Dr. Sudakin has presented to community physicians and medical toxicology fellows and residents on topics relating to addiction medicine and forensic toxicology.
Timothy J. Wiegand, MD, FACMT is an Associate Clinical Professor in the Department of Emergency Medicine at the University of Rochester Medical Center and is Director of the bedside Toxicology Consult Service at Strong Memorial Hospital and Highland Hospital and of the outpatient Toxicology Consultation Clinic at Strong Memorial Hospital in Rochester, New York. Dr. Wiegand is Board Certified in both Internal Medicine as well as Medical Toxicology and completed additional fellowship training in Clinical Pharmacology at the University of California, San Francisco. Dr. Wiegand’s practice revolves mostly around the delivery of consultation toxicology, pharmacology and addiction services although has also been involved in poisoning prevention serving as either consultant or Assistant/Associate Medical Director Positions for several different Poison Control Centers including the San Francisco Division of the California Poison Control System and the Northern New England Poison and Drug Information Center before moving to Rochester and becoming the Director of the Ruth Lawrence Poison & Drug Information Center. He is currently a consultant toxicologist for the SUNY Upstate Poison Center and active in their toxicology fellowship program. One of Dr. Wiegand’s particular interests is the intersection of addiction medicine and medical toxicology. He Chairs the Addiction Medicine Section for the American College of Medical Toxicology. Dr.Wiegand has an addiction medicine pharmacotherapy clinic at Huther-Doyle Chemical Dependency Treatment program, a 500-600 person capacity comprehensive drug and alcohol dependence treatment program in Rochester, New York and he became the Medical Director of Huther-Doyle in September, 2012.